IMV

At IMV, we have created a unique non-aqueous, lipid-based delivery technology called DPX, which can incorporate an array of bioactive molecules into a single formulation to create long-lasting, targeted immune responses that mitigate disease without severe toxicity. It allows us to package and deliver a wide array of bioactive cargo including peptides, whole proteins, RNA, DNA, small molecules, and virus-like particles. DPX has the capability of driving targeted and durable immune responses. Cancer vaccines have historically failed to provide clinical benefits for cancer patients. Thanks to the uniquely oil-based formulation, DPX is designed to prevent release of packaged bioactive agents into tissues.